Nonetheless, to circumvent these potential concerns, we decided to focus on the direct effects of SND1 on ECs instead and hypothesized that pharmacological reversal of broad transcriptional changes caused by SND1 KD in ECs may protect against sunitinib-induced endothelial dysfunction. This evidence concerns the gene SND1 and endothelial dysfunction.